Innate Pharma 6-K Filing Incorporates into F-3 and S-8 Registrations

Ticker: IPHYF · Form: 6-K · Filed: Feb 18, 2025 · CIK: 1598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type6-K
Filed DateFeb 18, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, registration-statement, foreign-private-issuer

TL;DR

Innate Pharma 6-K filed, referencing F-3 and S-8 registration statements.

AI Summary

Innate Pharma S.A. filed a Form 6-K on February 18, 2025, reporting information as of February 17, 2025. The filing incorporates by reference into existing registration statements on Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031). The company is a foreign private issuer incorporated in France.

Why It Matters

This filing indicates that Innate Pharma is updating or referencing its existing registration statements, which is a standard procedural step for companies with publicly traded securities.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain new material financial information or significant operational updates that would typically increase risk.

Key Players & Entities

  • Innate Pharma S.A. (company) — Registrant
  • 333-276164 (dollar_amount) — Form F-3 File Number
  • 333-282031 (dollar_amount) — Form S-8 File Number

FAQ

What is the purpose of this Form 6-K filing by Innate Pharma S.A.?

The Form 6-K is a report of a foreign private issuer and in this instance, it is being incorporated by reference into existing registration statements on Form F-3 (File No. 333-276164) and Form S-8 (File No. 333-282031).

What is the filing date and reporting period for this Innate Pharma 6-K?

The filing date is February 18, 2025, and the conformed period of report is February 17, 2025.

Where is Innate Pharma S.A. incorporated and what is its principal executive office address?

Innate Pharma S.A. is incorporated in France, and its principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.

Does Innate Pharma file annual reports under Form 20-F or Form 40-F?

Innate Pharma indicates it files annual reports under cover of Form 20-F.

What are the file numbers for the registration statements into which this 6-K is incorporated?

This 6-K is incorporated into registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333-282031).

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on February 18, 2025 regarding Innate Pharma SA (IPHYF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.